Enterprise Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 14
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Latest Deal Amount
  • $97.9M
Latest Deal Amount
  • Investors
  • 7

Enterprise Therapeutics General Information

Description

Developer of novel therapies designed for the treatment of respiratory diseases. The company's scientific strategy is aimed at discovering new disease-modifying therapies that target the underlying mechanisms of mucus congestion, enabling patients to reduce the frequency of lung infections and improve patient quality of life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Sussex Innovation Centre
  • University of Sussex, Science Park Square, Falmer
  • Brighton BN1 9SB
  • England, United Kingdom
+44 01273 000000

Enterprise Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Enterprise Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 06-Oct-2020 $97.9M 000.00 000.00 Completed Generating Revenue
4. Grant 15-Oct-2019 00.000 000.00 Completed Generating Revenue
3. Early Stage VC (Series B) 12-Apr-2018 000.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC 10-Nov-2016 $5.43M $11.6M 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 20-May-2015 $6.15M $6.15M 00.00 Completed Startup
To view Enterprise Therapeutics’s complete valuation and funding history, request access »

Enterprise Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Enterprise Therapeutics’s complete cap table history, request access »

Enterprise Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapies designed for the treatment of respiratory diseases. The company's scientific strategy is ai
Drug Discovery
Brighton, United Kingdom
14 As of 2021
000.00
00.00 0000-00-00
00000000000 000.00

0000000

agna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
0000 000000000
Stevenage, United Kingdom
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

00000000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000 000000000
Tucson, AZ
0 As of 0000
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Enterprise Therapeutics Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ReViral Venture Capital-Backed Stevenage, United Kingdom 00 00000 00000000000 00000
00000000 000000000 Corporation Tucson, AZ 0 0000000000
000000 000000 Accelerator/Incubator Backed Morristown, NJ 0 00.000 0000000000 00.000
0000 000000000000 Venture Capital-Backed Oxford, United Kingdom 000 00000 00000000000 00000
00000000 Venture Capital-Backed San Francisco, CA 00 00000 0000000000 00000
You’re viewing 5 of 19 competitors. Get the full list »

Enterprise Therapeutics Patents

Enterprise Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210188855-A1 Compounds Pending 18-May-2018 0000000000
JP-2021524453-A Compound Pending 18-May-2018 0000000000
EP-3794002-A1 Compounds Pending 18-May-2018 0000000000
GB-201808093-D0 Compounds Ceased 18-May-2018 0000000000
US-20200361871-A1 Compounds Pending 26-Jan-2018 C07D213/81
To view Enterprise Therapeutics’s complete patent history, request access »

Enterprise Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
John Ford Ph.D Chief Executive Officer & Board Member
Martin Gosling Ph.D Chief Scientific Officer & Co-Founder
Henry Danahay Ph.D Co-Founder & Head of Biology
You’re viewing 3 of 5 executive team members. Get the full list »

Enterprise Therapeutics Board Members (11)

Name Representing Role Since
Alexander Mayweg Ph.D Versant Ventures Board Member 000 0000
Amit Munshi Self Chairman 000 0000
Bart Dzikowski JD Self Board Member 000 0000
Craig Richardson Ph.D IP Group Board Member 000 0000
Geert-Jan Mulder MD Forbion Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Enterprise Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enterprise Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Roche Holding Corporation Minority 000 0000 000000 0
Cystic Fibrosis Foundation Corporation 000 0000 000000 0
Forbion Venture Capital Minority 000 0000 000000 0
IP Group Venture Capital Minority 000 0000 000000 0
Versant Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »